iRhythm Technologies Inc. recently delivered a presentation highlighting its advances in cardiac diagnostics and monitoring at the J.P. Morgan 44th Annual Healthcare Conference. The company reported anticipated full-year 2025 revenue of over $740 million and noted that approximately 2.6 million patient reports are posted annually. iRhythm emphasized the use of patented wearable biosensors and FDA-cleared, AI-driven ECG detection algorithms to address the growing need for ambulatory cardiac monitoring, particularly among the aging population and in underserved rural areas. The company cited market expansion opportunities in the United States and internationally, with a target market of 27 million potential patients in the U.S. and 3.2 million tests across prioritized EU and APAC countries. iRhythm also reported a core U.S. market penetration of approximately 40% as of December 31, 2025. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments